Multiple sclerosis is treatable, though not yet curable. Over 20 FDA-approved medications can slow the disease, reduce flare-ups, and manage symptoms, and the treatment landscape has expanded dramatically in the past two decades. Most people with MS now have access to therapies that meaningfully change the course of their disease, and the gap in life expectancy between people with MS and the general population has narrowed as treatments have improved.
How MS Treatments Work
MS happens when the immune system mistakenly attacks the protective coating around nerve fibers in the brain and spinal cord. This coating, called myelin, insulates nerves the way rubber insulates electrical wiring. When it’s damaged, nerve signals slow down, scatter, or stop entirely, which produces the wide range of symptoms MS is known for.
The main category of MS treatment is called disease-modifying therapy, or DMT. These medications don’t repair damage that’s already occurred. Instead, they target the immune system to prevent new attacks. Some work by keeping immune cells trapped in lymph nodes so they can’t reach the brain. Others deplete specific immune cells entirely or shift the immune response away from the aggressive pattern that damages myelin. A newer class of injectable therapies works by blocking immune cells from crossing the blood-brain barrier, essentially locking them out of the central nervous system.
Current DMTs reduce the annual relapse rate by anywhere from 29% to 68% compared to placebo, depending on the specific medication. That’s a wide range, and it reflects the fact that some drugs are considered “platform” therapies (moderate effectiveness, well-established safety profiles) while others are high-efficacy options that suppress the disease more aggressively but carry greater risks.
Relapsing vs. Progressive MS
The type of MS you have determines which treatments are available. Most people are initially diagnosed with relapsing-remitting MS, where symptoms flare up and then partially or fully improve. The majority of approved DMTs target this form, and many people on these medications go years without a relapse or new brain lesions on MRI.
Progressive MS is harder to treat. In this form, disability accumulates gradually without distinct flare-ups. For years, there were no approved therapies for primary progressive MS. That changed when ocrelizumab became the first medication approved for both relapsing and primary progressive forms. It works by depleting a type of immune cell called B-cells and has been shown to slow the progression of disability in primary progressive MS, though the effect is more modest than what’s seen in the relapsing form. In 2024, the FDA approved a subcutaneous version of this drug, making it easier to administer.
Managing Relapses
Even with a DMT, relapses can still happen. When they do, the standard treatment is a short course of high-dose intravenous steroids, typically given daily for three to five days. These don’t change the long-term course of the disease, but they reduce inflammation quickly and shorten the duration of a flare. Most people receive the infusion at an outpatient clinic and go home the same day. Side effects like trouble sleeping, elevated blood sugar, and stomach irritation are common but temporary.
Not every relapse needs steroid treatment. Mild sensory symptoms like tingling or numbness that don’t interfere with daily function sometimes resolve on their own within a few weeks.
Treating Everyday Symptoms
Living with MS often means managing a collection of symptoms that persist between relapses or worsen gradually. These require their own treatments, separate from DMTs.
Fatigue is the most common complaint, affecting the vast majority of people with MS. Treatment plans usually combine medication with energy conservation strategies, physical rehabilitation, and dietary adjustments. Spasticity, the muscle stiffness and involuntary spasms that can make movement difficult, is treated with muscle relaxants or targeted injections that calm overactive muscles. Bladder dysfunction, another frequent issue, responds to medications that relax the bladder wall and reduce urgency.
Walking difficulty has its own targeted treatment. A medication that works by improving nerve signal conduction along damaged fibers has been shown to meaningfully increase walking speed in about 35% of people who take it. Those who respond also report improvements on walking quality scales and overall function. The other 65% don’t see a benefit, so doctors typically prescribe a trial period to see if it helps before continuing.
Stem Cell Transplant as a Treatment
Hematopoietic stem cell transplant, or HSCT, is an intensive treatment that essentially reboots the immune system. The process involves collecting your own stem cells, using chemotherapy to wipe out the existing immune system, then reinfusing the stem cells to rebuild it from scratch. The goal is an immune system that no longer attacks myelin.
Results from clinical trials are striking. In one major trial comparing HSCT to standard DMTs, only about 10% of patients in the transplant group experienced disease progression over five years, compared to 75% in the DMT group. Relapse rates were also significantly lower. Another trial showed HSCT reduced new brain lesions by 79% compared to an alternative treatment, with the benefit holding over four years of follow-up.
HSCT works best in specific circumstances: younger patients (under 35 to 40), those with relapsing rather than progressive disease, people with active inflammation visible on MRI, those who haven’t been through many prior treatments, and those with lower levels of existing disability. It carries real risks, including infection during the period when the immune system is suppressed, and it requires hospitalization. It’s not a first-line option for most people, but for the right candidate, it can produce long-lasting remission.
What Treatment Means for Long-Term Outlook
MS is a lifelong condition, but the prognosis has improved substantially. Earlier data suggested people with MS lived about six to seven years less than the general population, and that gap has likely narrowed further with modern high-efficacy therapies that weren’t available when those numbers were calculated.
The key factor in long-term outcomes is starting treatment early. Brain lesions and nerve damage can accumulate silently even when you feel fine, and the goal of DMTs is to prevent that hidden damage from building up. People who begin effective treatment soon after diagnosis and stay on it consistently tend to have less disability over time than those who delay or stop treatment.
Treatment isn’t one-size-fits-all, and what works at diagnosis may not be the right choice five or ten years later. Most people with MS will adjust their treatment plan over time, switching medications as their disease evolves, new options become available, or side effects become a concern. The trajectory for someone diagnosed today is meaningfully different from someone diagnosed even 15 years ago, with more options, better monitoring, and a clearer understanding of when to escalate therapy.